These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29768755)

  • 21. Power of metabolomics in biomarker discovery and mining mechanisms of obesity.
    Zhang A; Sun H; Wang X
    Obes Rev; 2013 Apr; 14(4):344-9. PubMed ID: 23279162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum metabolomics analysis for early detection of colorectal cancer.
    Uchiyama K; Yagi N; Mizushima K; Higashimura Y; Hirai Y; Okayama T; Yoshida N; Katada K; Kamada K; Handa O; Ishikawa T; Takagi T; Konishi H; Kuriu Y; Nakanishi M; Otsuji E; Itoh Y; Naito Y
    J Gastroenterol; 2017 Jun; 52(6):677-694. PubMed ID: 27650200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolomics in urogenital cancer.
    Bujak R; Daghir E; Rybka J; Koslinski P; Markuszewski MJ
    Bioanalysis; 2011 Apr; 3(8):913-23. PubMed ID: 21510764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of colorectal cancer: recent advances and future challenges.
    Coghlin C; Murray GI
    Proteomics Clin Appl; 2015 Feb; 9(1-2):64-71. PubMed ID: 25311658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine.
    Ahluwalia P; Ballur K; Leeman T; Vashisht A; Singh H; Omar N; Mondal AK; Vaibhav K; Baban B; Kolhe R
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
    Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
    Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
    Furtado LV; Samowitz WS
    Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
    Patil H; Saxena SG; Barrow CJ; Kanwar JR; Kapat A; Kanwar RK
    Drug Discov Today; 2017 Jan; 22(1):111-119. PubMed ID: 27693431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine.
    Singh MP; Rai S; Pandey A; Singh NK; Srivastava S
    Genes Dis; 2021 Mar; 8(2):133-145. PubMed ID: 33997160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
    Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
    Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.
    Del Boccio P; Rossi C; di Ioia M; Cicalini I; Sacchetta P; Pieragostino D
    Proteomics Clin Appl; 2016 Apr; 10(4):470-84. PubMed ID: 27061322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Metabolome Analysis of Human Serum: Implications for Early Detection of Colorectal Cancer].
    Yamazaki Y
    Rinsho Byori; 2015 Mar; 63(3):328-35. PubMed ID: 26524856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers.
    Wang H; Liang L; Fang JY; Xu J
    Oncogene; 2016 Apr; 35(16):2011-9. PubMed ID: 26257062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolomics in chronic kidney disease.
    Zhao YY
    Clin Chim Acta; 2013 Jun; 422():59-69. PubMed ID: 23570820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of metabolomic approaches for Chinese medicine syndromes and herbal medicine.
    Sun H; Zhang A; Wang X
    Phytother Res; 2012 Oct; 26(10):1466-71. PubMed ID: 22422429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment.
    Zhang A; Sun H; Wang X
    Appl Biochem Biotechnol; 2012 Nov; 168(6):1718-27. PubMed ID: 22971835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolomics for mitochondrial and cancer studies.
    Nagrath D; Caneba C; Karedath T; Bellance N
    Biochim Biophys Acta; 2011 Jun; 1807(6):650-63. PubMed ID: 21420931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Personalized medicine--the future is already here].
    Abadi-Korek I; Shemer J
    Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.